ABBOTT PARK, Ill., Nov. 22 /PRNewswire/ -- Abbott Laboratories today
announced it has acquired certain assets of Glaxo Wellcome Inc.'s anesthesia
business in the United States. Financial terms of the agreement were not
Included in the acquisition are four neuromuscular blockers (muscle
relaxants) and Ultiva(R) (remifentanil), an ultra-short acting analgesic.
Abbott obtains rights to the related trademarks, intellectual property,
clinical data, regulatory files and manufacturing know-how pertaining to the
"These products are an excellent fit with our current perioperative and
intensive care product offerings. Today's agreement enhances an already
extensive line of Abbott anesthesia products for our customers," said Richard
A. Gonzalez, senior vice president, hospital products. "Each of these
products can be used in conjunction with our inhaled anesthesia agents and are
well suited for use in the growing ambulatory surgery setting."
The four neuromuscular blockers include three proprietary products,
Nimbex(R) (cisatracurium), Mivacron(R) (mivacurium) and Nuromax(R)
(doxacurium), as well as Tracrium(R) (atracurium). All four products are used
as adjuncts to general anesthesia but work for varying lengths of time. The
products can be used prior to surgery to ease endotracheal intubation and
during surgery to facilitate skeletal muscle relaxation and mechanical
Ultiva(R) (remifentanil) is the first in a class of ultra-short acting
analgesics known as esterase opioids and is used in surgical, post surgical
and monitored anesthesia cases (when patients are awake during a surgical
procedure). With a very rapid onset and offset of action and an ease of
control by the clinician, the use of Ultiva(R) allows for repeated or
prolonged administration without the risk of drug accumulation and the
associated side effects of other opioids.
Abbott's perioperative and intensive care product line offers a proven
product for every phase of the anesthesia procedure from pre-medication,
through surgery and recovery and post-operative pain management. Products in
this franchise include inhalation and induction agents, local anesthetics,
analgesics and muscle relaxants. The sale of these products is supported by
one of the largest, hospital-based specialty sales forces focusing exclusively
on anesthesiologists and nurse anesthetists.
Abbott, a world leader in anesthesia products for more than 75 years,
manufactures and markets a broad range of anesthesia and pain management
products. These products include highly successful products like
Penthothal(R), launched more than 50 years ago and still an important
induction anesthetic; the first patient-controlled analgesia (PCA) system in
the United States; the first transmucosal drug delivery system for pediatric
and adult anesthetic premedication; the co-promotion of Anzemet(R), an
antiemetic for post-operative nausea and vomiting, and OxyContin(TM) for
post-operative pain; and Ultane(R) (sevoflurane), the leading inhalation agent
for pediatric and adult patients.
Abbott Laboratories is a global, diversified health care company devoted
to the discovery, development, manufacture and marketing of pharmaceutical,
diagnostic, nutritional and hospital products. The company employs 56,000
people and markets its products in more than 130 countries. In 1998, the
company's sales and net earnings were $12.5 billion and $2.3 billion,
respectively, with diluted earnings per share of $1.51.
Abbott's news releases and other information are available on the
company's Web site at www.abbott.com .
SOURCE Abbott Laboratories